Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹64 Cr revenue.
COGS 74.9%, employees 2.1%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 22.4%▲ | 10.5% |
| ROCE | 32.5%▲ | 13.8% |
| EBITDA Margin | 10.8%▼ | 16.0% |
| Debt To Equity | 0.29x▲ | 0.21x |
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹64 Cr +171.6% | ₹24 Cr +589.8% | ₹3 Cr | ₹0.00 Cr -100.0% | ₹0.20 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Income | ₹0.13 Cr +833.6% | ₹0.01 Cr -92.5% | ₹0.18 Cr -15.2% | ₹0.21 Cr | ₹0.00 Cr -100.0% | ₹0.20 Cr -31.8% | ₹0.30 Cr |
| Total Income | ₹64 Cr +172.0% | ₹24 Cr +556.0% | ₹4 Cr | ₹0.21 Cr +3.8% | ₹0.20 Cr -0.8% | ₹0.20 Cr -31.8% | ₹0.30 Cr |
| COGS | ₹48 Cr +125.5% | ₹21 Cr +536.1% | ₹3 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹52 Cr +132.0% | ₹23 Cr +531.5% | ₹4 Cr | ₹0.23 Cr +16.8% | ₹0.20 Cr -16.3% | ₹0.23 Cr -38.0% | ₹0.38 Cr | |
| Profit Before Tax | ₹12 Cr | ₹1 Cr | ₹0.03 Cr ↑ Recovery | (₹0.02 Cr) ↓ Decline | ₹0.01 Cr ↑ Recovery | (₹0.03 Cr) +62.7% | (₹0.08 Cr) |
| Exceptional Items | (₹0.00 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹3 Cr +911.0% | ₹0.30 Cr | ₹0.02 Cr | ₹0.00 Cr -95.2% | ₹0.00 Cr | ₹0.00 Cr -98.5% | ₹0.01 Cr | |
| Net Profit | ₹9 Cr | ₹0.78 Cr | ₹0.02 Cr ↑ Recovery | (₹0.02 Cr) ↓ Decline | ₹0.01 Cr ↑ Recovery | (₹0.03 Cr) +65.7% | (₹0.08 Cr) |
| EPS | ₹9.08 | ₹0.80 | ₹0.04 | (₹0.04) | ₹0.02 | (₹0.07) | (₹0.21) |
| Diluted Shares | ₹0.98 Cr | ₹0.98 Cr | ₹0.40 Cr | ₹0.40 Cr | ₹0.40 Cr | ₹0.40 Cr | ₹0.40 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Submission of newspaper publication for financial results for the quarter and year ended March, 2026.
Annual Secretarial Compliance Report for the period March 31, 2026.
Intimation of appointment of statutory auditor in material wholly owned subsidiary company to fill the casual vacancy due to resignation.
Submission of intimation of resignation of statutory auditors of Sriven Pharmachem India Private limited a material subsidiary of the Company.
Submission of website intimation.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aceso Research Labs LLP
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aceso Research Labs LLP
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aceso Research Labs LLP
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sesha Sai Nikhil Chintalapati
Submission of Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Doradla Radha Krishna HUF & Others
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suryanarayana Raju Rudraraju & Others
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sesha Sai Nikhil Chintalapati & Others
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kommera Harish
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Chandra Sekhar Reddy & Vupparapalli Pavani
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
No dividend history available for this company.